Novelos Therapeutics to Present and Webcast at Roth 19th Annual OC Conference.NEWTON, Mass. -- Novelos Therapeutics, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : NVLT NVLT Novelos Therapeutics, Inc (stock symbol) NVLT Night Vision Low-Tech (US Army program) ), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Harry S. Palmin, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Novelos, will present at the Roth Capital Partners Roth Capital Partners, LLC, is a full service Investment Banking firm, specializing in the small and micro cap markets. Roth’s focus, according to its official website, "has been, is, and will continue to be providing the full spectrum of investment banking services, 19th Annual OC Conference on Thursday, February 22, 2007. Mr. Palmin is scheduled to present at 11am EST EST electroshock therapy. EST abbr. electroshock therapy (8am PST PST Paroxysmal supraventricular tachycardia, see there ) in the Ritz Ballroom, Salon 1. The event will be held at the Ritz Carlton, Laguna Niguel, CA. A live webcast of Mr. Palmin's presentation may be accessed via www.novelos.com The webcast will be archived for 90 days following the presentation. Information about the conference is available at www.rothconference.com About Novelos Therapeutics, Inc. Novelos Therapeutics, Inc. is a biotechnology company commercializing oxidized oxidized having been modified by the process of oxidation. oxidized cellulose see absorbable cellulose. glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under a SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and an immunomodulator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer, and is in addition being developed for acute radiation injury. NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were originally developed. For additional information about Novelos please visit www.novelos.com Novelos Therapeutics, Inc. One Gateway Center, Suite 504 Newton, MA 02458 This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion